- Home
- HUMA vs NBP Comparison
HUMA vs NBP Comparison
Compare HUMA & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | NBP |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 149.2M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HUMA | NBP |
|---|---|---|
| Price | $0.60 | $0.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.64 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 5.3M | 497.4K |
| Earning Date | 11-10-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,038,000.00 | N/A |
| Revenue This Year | $78.59 | N/A |
| Revenue Next Year | $570.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.82 |
| 52 Week High | $1.53 | $5.19 |
Technical Indicators
Market Signals| Indicator | HUMA | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 18.73 |
| Support Level | $0.54 | N/A |
| Resistance Level | $0.61 | $1.45 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 85.43 | 1.09 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.